Teligent, a New Jersey-based specialty generic pharmaceutical company, has received approval of the company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Erythromycin Topical Gel USP, 2%. This is Teligent's third approval for 2017, and its fourteenth approval from its internally-developed pipeline of topical generic pharmaceutical medicines.
Based on recent QuintilesIMS Health data from May 2017, the total addressable market for this product is approximately $17.6 million.
"Erythromycin Topical Gel USP, 2% is Teligent's third FDA approval in 2017,'' commented Jason Grenfell-Gardner, President and CEO of Teligent. "Teligent now has nineteen topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products. We expect to launch this product in the third quarter of 2017."